SP140L Antibody

What is SP140L and why is it important in immunological research?

SP140L (SP140 nuclear body protein like) is a transcriptional regulatory protein belonging to the SP100 family. In humans, the canonical form consists of 580 amino acid residues with a molecular mass of 67 kDa . Its importance in immunology stems from several key characteristics:

SP140L is expressed in immune cells, particularly B cells and peripheral blood mononuclear cells, with expression being interferon-inducible . Research has identified SP140L as an autoantigen in primary biliary cirrhosis patients, making it relevant for autoimmune disease investigations . Additionally, the PHD (plant homeodomain) finger of SP140L is specifically recognized by anti-Mi2 autoantibodies in myositis patients, showing 92% sensitivity in detection assays .

Understanding SP140L function provides insights into transcriptional regulation in immune cells and potential mechanisms of autoimmunity, particularly given its recent evolutionary emergence in higher primates through rearrangements of the neighboring SP100 and SP140 genes .

What experimental applications are suitable for SP140L antibodies?

SP140L antibodies can be utilized across multiple experimental platforms:

When selecting antibodies, researchers should consider the specific applications required, target epitopes (particularly when studying the PHD domain), and species reactivity . For autoimmunity studies, the Luciferase Immunoprecipitation System (LIPS) has proven effective for detecting anti-SP140L autoantibodies in patient sera .

How is SP140L structurally and functionally related to other SP100 family proteins?

SP140L shares significant structural and functional relationships with other SP100 family members:

• Genomic organization: The SP100 family genes (SP100, SP110, SP140, and SP140L) cluster on chromosome 2q37.1 .

• Evolutionary relationship: SP140L is a phylogenetically recent addition, formed through rearrangements of SP100 and SP140 genes during primate evolution .

• Domain architecture: Like other family members, SP140L contains a PHD zinc finger domain important for protein-protein interactions. The PHD domain of SP140L differs from SP140 by only two amino acids .

• Subcellular localization: SP140L colocalizes with SP100 and SP140 in specific nuclear structures that are distinct from those containing SP110, PML, or p300 proteins .

• Functional overlap: All SP100 family members participate in transcriptional regulation, with SP140L and SP140 showing more restricted expression patterns than the widely expressed SP100 .

This relationship suggests that research findings regarding one family member might provide insights into others, though their specific functions may have diverged during evolution.

What protocols are recommended for visualizing SP140L subcellular localization?

For optimal visualization of SP140L's nuclear localization pattern, the following protocol is recommended:

• Cell preparation:

  • Grow cells on coverslips or use cytospin for suspension cells

  • For induced expression, treat cells with interferon for 24-48 hours

• Fixation and permeabilization:

  • Fix with 4% paraformaldehyde (15-20 minutes) to preserve nuclear structure

  • Permeabilize with 0.1-0.5% Triton X-100 to allow antibody access to nuclear proteins

• Immunostaining:

  • Block with BSA or normal serum (1 hour)

  • Incubate with anti-SP140L primary antibody (1:50-1:200 dilution, overnight at 4°C)

  • Wash thoroughly with PBS

  • Apply fluorophore-conjugated secondary antibody (1:500-1:1000, 1 hour)

  • Counterstain nucleus with DAPI or Hoechst

• Co-localization studies:

  • Use antibodies against SP100 and SP140 (positive controls)

  • Include SP110, PML, or p300 antibodies (negative controls)

  • Apply different color fluorophores for each protein

• Microscopy:

  • Confocal microscopy provides optimal resolution for nuclear structures

  • Use Z-stacking to capture the full nuclear volume

  • Analyze co-localization using appropriate software (e.g., ImageJ with co-localization plugins)

Expected results: SP140L will appear as distinct punctate structures within the nucleus, showing significant overlap with SP100 and SP140 but not with SP110, PML, or p300 .

What are the key characteristics of SP140L protein that impact experimental design?

Understanding SP140L's key characteristics is essential for designing robust experiments:

• Protein characteristics:

  • Canonical form: 580 amino acids, 67 kDa molecular weight

  • Four different isoforms reported

  • Contains a PHD zinc finger domain (~49 amino acids)

• Expression pattern:

  • Interferon-inducible expression

  • Highest expression in B cells and other peripheral blood mononuclear cells

  • Consider cell activation state when studying expression

• Subcellular localization:

  • Nuclear localization in discrete structures

  • Co-localizes with SP100 and SP140

  • Distinct from structures containing SP110, PML, or p300

• Functional aspects:

  • Involved in transcriptional regulation

  • Potential role in immune cell function

  • Autoantigen in certain autoimmune conditions

• Species considerations:

  • Relatively recent evolutionary emergence in higher primates

  • Orthologs reported in chimpanzees but consider evolutionary differences when using animal models

These characteristics should inform sample preparation, antibody selection, experimental controls, and data interpretation when working with SP140L.

How can researchers design studies to investigate SP140L's role in autoimmune diseases?

Investigating SP140L in autoimmune conditions requires a multi-faceted approach:

• Patient cohort characterization:

  • Screen for anti-SP140L autoantibodies in various autoimmune diseases

  • Design cohorts similar to previous studies:

  Group	Sample Size	Disease Criteria	Controls
  Primary biliary cirrhosis	50+	Confirmed diagnosis	Age/sex matched
  Myositis	50+	Lloyd's or Casal/Pinal criteria	Age/sex matched
  Other autoimmune diseases	30-50 per condition	Standard diagnostic criteria	Age/sex matched
  Healthy controls	100+	No autoimmune history	Demographically diverse

• Autoantibody characterization methodologies:

  • LIPS assay for sensitive detection of anti-SP140L autoantibodies

  • Test both full-length SP140L and the isolated 49-amino-acid PHD domain

  • Compare autoantibody profiles between different autoimmune conditions

• Functional studies:

  • Investigate if patient-derived anti-SP140L autoantibodies can penetrate cells

  • Assess whether autoantibodies disrupt SP140L's transcriptional regulatory function

  • Study potential cross-reactivity with other PHD finger-containing proteins

• Transcriptomic analysis:

  • Compare gene expression profiles in cells with:
    a) SP140L knockdown
    b) SP140L overexpression
    c) Exposure to anti-SP140L autoantibodies

  • Focus on immune-related pathways and interferon-responsive genes

• Cellular models:

  • Use B cells or interferon-stimulated cells with endogenous SP140L expression

  • Develop CRISPR-modified cell lines with SP140L mutations matching patient variants

  • Test functional consequences of SP140L disruption on immune cell responses

These approaches can help elucidate whether SP140L dysfunction contributes to autoimmune pathogenesis and potentially identify new therapeutic targets.

What methodological approaches should be employed to study interactions between SP140L's PHD domain and anti-Mi2 autoantibodies?

Investigating interactions between SP140L's PHD domain and anti-Mi2 autoantibodies requires specialized methodological approaches:

• Domain-specific binding analysis:

  • Express and purify recombinant constructs:
    a) Full-length SP140L
    b) Isolated PHD domain (49-amino-acid segment)
    c) Alanine scanning mutants of the PHD domain

  • Test binding using multiple techniques:

  Technique	Advantage	Expected Results
  LIPS assay	High sensitivity	92% of anti-Mi2+ sera recognize PHD domain
  Surface Plasmon Resonance	Binding kinetics	Measure affinity constants
  ELISA	High-throughput	Quantitative comparison across patient cohorts

• Structural characterization:

  • X-ray crystallography or NMR of the SP140L PHD domain

  • Focus on the two amino acid differences from SP140's PHD domain

  • Molecular modeling of antibody-PHD domain interactions

  • Identify critical binding residues through mutagenesis

• Cross-reactivity assessment:

  • Compare recognition patterns with other PHD-containing proteins (Mi2, AIRE)

  • Competitive binding assays to determine relative affinities

  • Pre-absorb patient sera with one PHD domain and test remaining reactivity to others

• Functional consequences:

  • Investigate whether anti-Mi2 autoantibodies interfere with:
    a) PHD domain zinc coordination
    b) Protein-protein interactions mediated by the PHD domain
    c) Chromatin binding properties

  • Compare effects of patient-derived monoclonal antibodies with different epitope specificities

• Cellular studies:

  • Test if anti-Mi2 autoantibodies can internalize and access nuclear SP140L

  • Examine whether antibody binding disrupts SP140L localization

  • Assess downstream effects on gene expression

This comprehensive approach can help determine whether targeting of multiple PHD finger-containing proteins by anti-Mi2 autoantibodies contributes to disease pathogenesis in myositis.

What techniques are most effective for studying SP140L's evolutionary relationship to other SP100 family members?

Studying SP140L's evolutionary origins requires specialized comparative genomics approaches:

• Phylogenetic analysis protocol:

  • Retrieve SP100 family sequences across species ranging from non-primate mammals to higher primates

  • Perform multiple sequence alignment focusing on conserved domains

  • Construct phylogenetic trees using maximum likelihood or Bayesian methods

  • Calculate evolutionary rates (dN/dS ratios) to identify regions under selection pressure

• Genomic organization assessment:

  • Analyze synteny (gene order conservation) around the SP100 locus across species

  • Identify genomic rearrangements that led to SP140L formation in higher primates

  • Examine intron-exon boundaries across family members

  • Investigate potential roles of repetitive elements in facilitating recombination events

• Expression evolution studies:

  • Compare tissue-specific expression patterns across species

  • Analyze promoter regions to identify conserved and divergent regulatory elements

  • Focus on interferon response elements and lymphoid-specific regulatory motifs

  • Use reporter assays to test functionality of ancestral vs. modern regulatory sequences

• Domain architecture analysis:

  • Track the evolution of functional domains across SP100 family members

  • Focus on the PHD finger and other conserved motifs

  • Identify domain gain/loss events during evolution

  • Predict functional consequences of domain arrangements unique to SP140L

• Ancestral sequence reconstruction:

  • Employ computational methods to infer ancestral sequences

  • Model the evolutionary events leading to SP140L formation

  • Date the emergence of SP140L using molecular clock approaches

  • Validate predictions by testing functional properties of reconstructed ancestral proteins

This systematic approach can provide insights into how SP140L emerged as a recent addition to the SP100 family and what functional innovations it might contribute to immune regulation in higher primates.

How might researchers explore SP140L's potential in cancer immunotherapy based on findings about related proteins?

SP140L's potential role in cancer immunotherapy can be investigated based on findings about related proteins, particularly SP140:

• Expression analysis in tumor microenvironment:

  • Analyze SP140L expression in:
    a) Tumor cells
    b) Tumor-associated macrophages (TAMs)
    c) Tumor-infiltrating lymphocytes

  • Compare expression patterns in responders vs. non-responders to immunotherapy

  • Correlate with immune infiltration patterns and clinical outcomes

• Functional characterization in immune cells:

  • Based on SP140's role in inducing IFN-γ and proinflammatory phenotypes in TAMs:
    a) Overexpress or knock down SP140L in macrophages
    b) Assess effects on polarization (M1 vs. M2)
    c) Measure cytokine/chemokine production (IL-12, CXCL10, IFN-γ)
    d) Evaluate antitumor activity in co-culture systems

  Parameter	Measurement Method	Expected Outcome (if similar to SP140)
  Macrophage polarization	Flow cytometry (CD80, CD86, CD206)	Shift toward M1 (proinflammatory)
  Cytokine production	ELISA, multiplex assay	Increased IL-12, CXCL10, IFN-γ
  STAT1 signaling	Phospho-flow, Western blot	Altered phosphorylation patterns
  T cell activation	Co-culture assays	Enhanced T cell proliferation and function

• Biomarker development strategy:

  • Assess SP140L expression in tumor biopsies pre/post-immunotherapy

  • Correlate expression with response to immune checkpoint inhibitors

  • Compare predictive value to established biomarkers like PD-L1

  • Develop immunohistochemistry protocols for clinical application

• Mechanistic studies:

  • Investigate SP140L's role in:
    a) Regulation of immune checkpoint molecules
    b) Antigen presentation pathways
    c) Interferon signaling networks

  • Determine whether SP140L's transcriptional regulatory function affects genes involved in antitumor immunity

• Therapeutic targeting approaches:

  • If SP140L functions similarly to SP140 in promoting antitumor immunity:
    a) Develop methods to enhance SP140L expression/activity
    b) Test combination approaches with checkpoint inhibitors
    c) Consider potential for autoimmune side effects given SP140L's role as an autoantigen

This research direction bridges findings on SP140's established role in cancer immunotherapy with SP140L's potential contributions, providing a framework for investigation while acknowledging the need for direct experimental validation.

What are the recommended approaches for studying SP140L's role in transcriptional regulation?

Investigating SP140L's role in transcriptional regulation requires specialized molecular approaches:

• Genome-wide binding site identification:

  • Chromatin immunoprecipitation followed by sequencing (ChIP-seq)

  • CUT&RUN or CUT&Tag for improved sensitivity and specificity

  • Analyze binding motifs and genomic distribution patterns

  • Compare SP140L binding sites with other SP100 family members

• Transcriptional impact assessment:

  • RNA-seq following SP140L modulation (knockout, knockdown, or overexpression)

  • Focus on interferon-stimulated cells where SP140L is highly expressed

  • Time-course analysis to distinguish direct vs. indirect effects

  • Pathway enrichment analysis of differentially expressed genes

• Protein complex characterization:

  • Immunoprecipitation coupled with mass spectrometry

  • BioID or APEX proximity labeling to identify proteins in close proximity

  • Focus on transcriptional machinery components and chromatin modifiers

  • Validate key interactions using co-immunoprecipitation or proximity ligation assay

• PHD domain functional analysis:

  • The PHD finger domain typically recognizes modified histone tails

  • Peptide binding assays with histone tail modifications

  • Mutational analysis of critical residues in the PHD domain

  • Compare binding specificity with related PHD fingers from SP140 and other proteins

• Nuclear body function investigation:

  • Live-cell imaging to track SP140L dynamics within nuclear bodies

  • FRAP (Fluorescence Recovery After Photobleaching) to assess mobility

  • Correlate nuclear body formation with transcriptional activity

  • Investigate relationship with other nuclear body components (SP100, SP140)

• Context-dependent regulation:

  • Compare SP140L function across different cell types

  • Analyze effects under various stimulation conditions:
    a) Interferon treatment
    b) Immune cell activation
    c) Stress conditions

  • Assess potential stress-responsive transcriptional programs

These approaches can help elucidate SP140L's specific role in transcriptional regulation and how it might contribute to immune function through modulation of gene expression programs.